Forte Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
FBRX Nasdaq 2836 www.fortebiorx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Forte Biosciences, Inc.

Top Midday Decliners - Jun 25th, 2025 12:44 pm
Forte Biosciences Announces Pricing of $75 Million Public Offering - Jun 24th, 2025 10:28 pm
Forte Biosciences Announces Proposed Public Offering - Jun 24th, 2025 2:01 pm
Forte Biosciences announces data from trial in celiac disease for FB102 - Jun 24th, 2025 11:06 am
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study - Jun 23rd, 2025 5:18 am
Forte Biosciences, Inc. Announces Results and Provides Update - May 15th, 2025 2:01 pm
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans? - Apr 1st, 2025 4:51 am
Forte Biosciences, Inc. Announces Results and Provides Clinical Update - Mar 31st, 2025 7:00 am
One Forte Biosciences Insider Raised Stake By 273% In Previous Year - Feb 19th, 2025 3:51 am
Forte Biosciences to Host R&D Day December 3, 2024 - Nov 25th, 2024 7:00 am
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications - Nov 20th, 2024 7:00 am
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update - Nov 14th, 2024 2:01 pm
Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested - Aug 26th, 2024 9:51 am
Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update - Aug 14th, 2024 2:01 pm